CG Oncology (CGON) Change in Accured Expenses (2023 - 2026)

CG Oncology's Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 92.22% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (down 9.63% YoY) and the FY2025 annual result came in at $8.7 million, up 58.28% from the prior year.
• Change in Accured Expenses was $1.6 million for Q1 2026 at CG Oncology, down from $3.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $7.5 million in Q2 2025 and bottomed at -$4.1 million in Q1 2024.
• A 4-year average of $1.5 million and a median of $1.6 million in 2026 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 2712.03% — and 2025, when it soared 263.53%.
• CG Oncology's Change in Accured Expenses stood at $1.8 million in 2023, then soared by 89.98% to $3.3 million in 2024, then advanced by 11.77% to $3.7 million in 2025, then slumped by 56.93% to $1.6 million in 2026.
• Business Quant data shows CGON's Change in Accured Expenses at $1.6 million in Q1 2026, $3.7 million in Q4 2025, and -$3.4 million in Q3 2025.